Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|August 3, 2017
Using RNA-Seq to Discover Genetic Polymorphisms That Produce Hidden Splice VariantsShayna Stein, Emad Bahrami-Samani, Yi Xing
Plos Computational Biology|January 3, 2018
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patientsShayna Stein, Rui Zhao, Hiroshi Haeno, et al.
Nucleic Acids Research|November 19, 2015
Discover hidden splicing variations by mapping personal transcriptomes to personal genomesShayna Stein, Zhi-Xiang Lu, Emad Bahrami-Samani, et al.
American Journal of Human Genetics|August 12, 2020
Detecting Allele-Specific Alternative Splicing from Population-Scale RNA-Seq DataLevon Demirdjian, Yungang Xu, Emad Bahrami-Samani, et al.
Cancer Research Communications|November 3, 2023
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast CancerYu-Chen Cheng, Shayna Stein, Agostina Nardone, et al.
Plos One|April 27, 2019
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategiesKimiyo N Yamamoto, Akira Nakamura, Lin L Liu, et al.
Gigascience|January 3, 2018
Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencingChao Fang, Huanzi Zhong, Yuxiang Lin, et al.
Cancer Discovery|May 4, 2021
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger Filho, Giuseppe Viale, Shayna Stein, et al.
JCI Insight|April 22, 2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancerMichalina Janiszewska, Shayna Stein, Otto Metzger Filho, et al.
Pageof 1